Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (114103)	4/29/2003 8:48:14 AM
From: StocksDATsoar	Respond to of 150070

B: SARS Drug Rumors Spread Faster Than Disease Itself Apr 28, 2003 (financialwire.net via COMTEX) -- (FinancialWire) While a summit of Asian health ministers was heading to Kuala Lumpur to plot how to contain severe acute respiratory syndrome, a handful of companies were raising the temperature of investors as rumors of SARS treatments spread through the markets faster than the disease itself. Among the companies benefiting from the various rumors and announcements were AVI Biopharma (NASDAQ: AVII), Medarex (NASDAQ: MEDX), Diacrin (NASDAQ: DCRN) and GenVec (NASDAQ: GNVC). AVI Biopharma gained 37.16% to $7.05 on Friday following a report that it had developed a therapy that killed the SARS coronavirus. However, in after hours trading it fell back to $5.75. Medarex traded as high as $4.80 before finally settling back to $4.15, a 6.66% gain, after it announced an agreement with the University of Massachusetts Medical School to co-develop human antibodies to SARS, Diacrin powered 60.93% to $3.46 after trading as high as $4.55, on word it is being acquired by GenVec, itself up 75.28%, after trading up to $3, following announcement that it has signed an agreement with the National Institutes of Health to undertake development of a clinical grade vaccine for the disease. In Maylasia, the health ministers approved screening of international travelers. Singapore already uses temperature screening machines that shows up as red spots on the faces of passengers with possible fever. Even villages surrounding Beijing are erecting roadblocks to keep out anyone from the capital city. Carnival Cruise Lines (NYSE: CCL) and Royal Caribbean Cruises (NYSE: RCL) have also begun rejecting passengers who have a temperature of 100.4 or who have visited Asia or Toronto. An advisory to its members from The Motley Fool warned against investing in companies on rumor, noting that even if a treatment made it through the testing and approval processes" those procedures take years. The site also said it's worth noting that neither company - Medarex and GenVec - has any products on the market." AVI BioPharma also announced that it has completed its preclinical development program for its proprietary NEUGENE antisense drug targeting the West Nile virus, and has begun formal discussions with the FDA about beginning clinical trials to avaluate its drug, AVI 4020. Until recently, AVI BioPharma was covered by an analyst in the unique Investrend independent analyst program, but the research is outdated. There is currently no professional analyst coverage to validate the company's business plans and developments. A survey at Investopedia reveals that 85.37% of investors say that "legitimate fee-based research is objective and useful," and 75.61% say that "a company that (enrolls in) a legitimate fee-based research (program) is making a positive statement about its investment potential." Complete information about any company enrolled in an Investrend shareholder empowerment platform, including disclosures and disclaimers, is available at the company's InvestorPower page at investrend.com For FinancialWire up-to-the-minute news, features and links click on financialwire.net For FinancialWire audio news, click on partner ON24 at on24news.com For instant traffic data on sites you visit, click on download.alexa.com FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. Investrend provides a wide range of forums, independent research and webcasting platforms for shareholder empowerment. For more information, Investrend may be contacted at investrend.com URL: financialwire.net (C) 2003 financialwire.net, Inc. All rights reserved. -0- * end of story *